| Schedule of financial information by reportable segments |
Financial information by reportable segment is as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended March 31, 2025 | | | Generics and Other | | Rare Disease and Brands | | Corporate and Unallocated | | Total | | Net Revenues | | $ | 103,040 | | $ | 94,082 | | $ | — | | | $ | 197,122 | | Less: | | | | | | | | | | Cost of sales (excluding depreciation and amortization) | | 46,501 | | | 26,536 | | | — | | | 73,037 | | | Research and development | | 6,588 | | | 3,976 | | | — | | | 10,564 | | | Selling, general, and administrative | | 1,408 | | | 42,436 | | | 32,684 | | | 76,528 | | | Depreciation and amortization | | — | | | — | | | 22,891 | | | 22,891 | | | Contingent consideration fair value adjustment | | — | | | — | | | (12,092) | | | (12,092) | | | Operating (Loss) Income | | $ | 48,543 | | $ | 21,134 | | $ | (43,483) | | $ | 26,194 | | | | | | | | | | | Unrealized loss on investment in equity securities | | $ | — | | | $ | — | | | $ | (921) | | | $ | (921) | | | Interest expense, net | | — | | | — | | | (5,484) | | | (5,484) | | | Other income, net | | — | | | — | | | 198 | | | 198 | | | Income (Loss) Before Income Tax Expense | | $ | 48,543 | | $ | 21,134 | | $ | (49,690) | | | $ | 19,987 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended March 31, 2024 | | | Generics and Other | | Rare Disease and Brands | | Corporate and Unallocated | | Total | | Net Revenues | | $ | 74,814 | | $ | 62,616 | | $ | — | | | $ | 137,430 | | Less: | | | | | | | | | | Cost of sales (excluding depreciation and amortization) | | 36,800 | | | 12,357 | | | — | | | 49,157 | | | Research and development | | 8,019 | | | 2,492 | | | — | | | 10,511 | | | Selling, general, and administrative | | 1,010 | | | 24,666 | | | 22,345 | | | 48,021 | | | Depreciation and amortization | | — | | | — | | | 14,686 | | | 14,686 | | | Contingent consideration fair value adjustment | | — | | | — | | | 90 | | | 90 | | | Gain on sale of building | | — | | | — | | | (5,347) | | | (5,347) | | | Operating (Loss) Income | | $ | 28,985 | | $ | 23,101 | | $ | (31,774) | | $ | 20,312 | | | | | | | | | | | Unrealized gain on investment in equity securities | | $ | — | | | $ | — | | | $ | 9,655 | | | $ | 9,655 | | | Interest expense, net | | — | | | — | | | (4,600) | | | (4,600) | | | Other expense, net | | — | | | — | | | (32) | | | (32) | | | Income (Loss) Before Income Tax Expense | | $ | 28,985 | | $ | 23,101 | | $ | (26,751) | | | $ | 25,335 | |
|